X4 Pharmaceuticals (XFOR)
3.85
+0.14 (3.77%)
Upcoming Events
Latest Headlines
Leerink Starts X4 Pharmaceuticals (XFOR) at Outperform
June 2, 2026 6:03 AM - StreetInsider
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 4:30 PM - Globe NewsWire
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026 7:00 AM - Globe NewsWire
Form EFFECT X4 Pharmaceuticals, Inc
May 18, 2026 6:04 AM - SEC Filing
Form SCHEDULE 13G/A X4 Pharmaceuticals, Inc Filed by: PERCEPTIVE ADVISORS LLC
May 15, 2026 4:01 PM - SEC Filing
Form 8-K/A X4 Pharmaceuticals, Inc For: May 11
May 13, 2026 4:58 PM - SEC Filing
Form 4 X4 Pharmaceuticals, Inc For: May 12 Filed by: KIRSKE DAVID
May 13, 2026 4:03 PM - SEC Filing
Form 144 X4 Pharmaceuticals, Inc Filed by: KIRSKE DAVID
May 12, 2026 6:11 PM - SEC Filing
Form 8-K X4 Pharmaceuticals, Inc For: May 11
May 12, 2026 4:22 PM - SEC Filing
X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 16c
May 7, 2026 6:05 AM - StreetInsider
Form S-3 X4 Pharmaceuticals, Inc
May 6, 2026 4:10 PM - SEC Filing
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026 7:15 AM - Globe NewsWire
Form 10-Q X4 Pharmaceuticals, Inc For: Mar 31
May 6, 2026 7:02 AM - SEC Filing
X4 Pharmaceuticals receives EU approval for WHIM syndrome treatment
April 29, 2026 7:01 AM - StreetInsider
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
April 29, 2026 7:00 AM - Globe NewsWire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2026 4:30 PM - Globe NewsWire
Form ARS X4 Pharmaceuticals, Inc For: Dec 31
March 20, 2026 9:08 AM - SEC Filing
Form DEFA14A X4 Pharmaceuticals, Inc
March 20, 2026 8:59 AM - SEC Filing
Form DEF 14A X4 Pharmaceuticals, Inc For: Mar 20
March 20, 2026 8:53 AM - SEC Filing
Form S-8 X4 Pharmaceuticals, Inc
March 18, 2026 6:04 AM - SEC Filing
Stifel stays Buy rated on X4 Pharmaceuticals (XFOR) as mavorixafor ph3 trial remains on-track
March 17, 2026 10:12 AM - StreetInsider
X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 22c
March 17, 2026 7:34 AM - StreetInsider
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 17, 2026 7:15 AM - Globe NewsWire
Form 10-K X4 Pharmaceuticals, Inc For: Dec 31
March 17, 2026 7:00 AM - SEC Filing
Full Article List
